Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

The Japanese Ministry of Health, Labour and Welfare (MHLW) has granted approval for the use of GSK’s Blenrep (belantamab ...

The revitalisation of GSK's blood cancer therapy Blenrep has continued with a second regulatory approval, in Japan, as a ...

The pharma company said it expects more approvals through the year following positive results from a Phase 3 trial.

Japan’s Ministry of Health, Labor and Welfare (MHLW) has approved UK pharma major GSK’s (LSE: GSK) Blenrep (belantamab ...

GSK’s Blenrep combinations receives Japanese approval for treatment of relapsed/refractory multiple myeloma: London, UK Tuesday, May 20, 2025, 12:00 Hrs [IST] GSK plc announced ...

GSK plc has received approval for Blenrep combinations from Japan's Ministry of Health, Labour and Welfare (MHLW) for the ...

(RTTNews) - British drug maker GSK plc (GSK.L, GSK) announced Monday the approval of Blenrep combinations by Japan's Ministry of Health, Labour and Welfare or MHLW for the treatment of adults with ...

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has authorised GSK’s Blenrep for treating multiple myeloma (MM).

(Alliance News) - GSK PLC on Monday said it has received approval in Japan for Blenrep combinations in the treatment of adults with relapsed or refractory multiple myeloma.

Investing.com -- GSK plc (LON: GSK ), a U.K.-based pharmaceutical company, said on Monday that its Blenrep combinations have been approved by Japan’s Ministry of Health. This approval is for the ...

GSK has received approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for Blenrep combinations to treat adults with relapsed or ...